Immune Cells and Secretory Pathways Leading to Human Systemic Autoimmunity

导致人类系统性自身免疫的免疫细胞和分泌途径

• 批准号: 10617208
• 负责人: Maria Virginia Pascual
• 金额: $ 67.8万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-05-01 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10617208
• 关键词: Address; Adult; Area; Autoimmune Diseases; Autoimmunity; B-Lymphocytes; Beds; Bioinformatics; Biological Assay; Biological Markers; Biology; Blood; CD4 Positive T Lymphocytes; CXCR3 gene; Cancer Biology; Cell Compartmentation; Cell physiology; Cells; Child; Child Health; Childhood; Classification; Clinical; Clinical Trials; Clinical Trials Design; Collaborations; Communicable Diseases; Complement; DNA; Data; Dedications; Dendritic cell activation; Development; Disease; Fibroblasts; Generations; Goals; Heterogeneity; Human; Hypersensitivity; Immune; Immune system; Immunology; In Vitro; Inflammation; Infrastructure; International; Knowledge; Lesion; Link; Longitudinal Studies; Lupus Nephritis; Malignant Neoplasms; Medicine; Metabolic; Molecular; Molecular Biology; Monitor; Myelogenous; Myeloid Cells; Neoplasm Metastasis; Nephritis; New York; Pathogenesis; Pathogenicity; Pathologic; Pathway interactions; Patients; Peripheral Blood Mononuclear Cell; Pharmaceutical Preparations; Physiological; Plasma; Population; Productivity; Recording of previous events; Research; Research Personnel; Resources; Role; Series; Software Engineering; Systemic Lupus Erythematosus; Systemic disease; T-Lymphocyte; T-Lymphocyte Subsets; Technology; Tissues; Translational Research; Work; autoinflammatory diseases; biomarker identification; cellular targeting; chronic inflammatory disease; cohort; disease heterogeneity; exosome; experience; extracellular; extracellular vesicles; high throughput technology; immunoregulation; insight; intercellular communication; interstitial; multidisciplinary; nanoparticle; new therapeutic target; novel; particle; patient oriented; patient stratification; personalized approach; personalized care; personalized medicine; programs; relapse prediction; response; stem; systemic autoimmune disease; systemic autoimmunity; technological innovation; tool; trafficking; treatment response; tumor; tumor microenvironment; uptake

The Autoimmunity Center of Excellence based at Weill Cornell Medicine (WCM) in New York, NY aims at 1) advancing the knowledge of pathways and mechanisms that contribute to the development and amplification of Human Systemic Autoimmune Diseases (SADs); 2) developing tools and identifying biomarkers to monitor these dysfunctional pathways. Ultimately, we aim to be able to stratify patients towards personalized approaches to treatment. The Center will employ ex vivo and in vitro high throughput technologies and immune profiling to gain insight into the contribution to disease of two major and complementary compartments contributing to systemic disease: Immune Cells and Extra-Cellular Nanoparticles. The appropriate infrastructure is in place to support patient- based studies. In particular, we emphasize the following key conceptual and technological innovations adding to our strengths, that include an established pediatric SLE cohort followed by experienced clinicians with an exceptional record of participation in translational research While the initial focus will be the study of children with Systemic Lupus Erythematosus (SLE), extrapolation of the Center findings to adult SLE as well as other SAD scenarios will be pursued, particularly in the context of the ACE Collaborative efforts. The Drukier Institute for Children’s Health Research at Weill Cornell Medicine has gathered a multidisciplinary team of pediatric basic and patient-oriented investigators with expertise in immunology, autoimmunity, cancer biology, molecular biology, bioinformatics and software engineers, who work together with clinical experts in autoimmunity, cancer, allergy and infectious diseases—from bed-to-bench and bench-to-bed—to understand and treat these diseases. The Institute has also established strong local, national and international collaborations. Dr. Pascual’s team has a long history of productive research in the fields of human autoinflammatory and autoimmune diseases. Dr. Lyden’s group has pioneered the study of exosomes and exomeres, and how these particles horizontally transfer their cargo to recipient cells, thereby acting as vehicles of intercellular communication in both physiological and pathological conditions. The proposed Center is a natural result of the very complementary expertise of these groups and is well-poised to work collaboratively to advance clinical and basic discoveries in the field of human autoimmunity. .

位于纽约州纽约的威尔康奈尔医学中心（WCM）的自身免疫卓越中心旨在1） 推进有助于发展和扩大的途径和机制的知识， 人类系统性自身免疫疾病（SAD）; 2）开发工具并鉴定生物标志物以监测这些疾病 功能失调的途径。最终，我们的目标是能够对患者进行个性化的方法分层， 治疗 该中心将采用离体和体外高通量技术和免疫分析， 两个主要的和互补的导致全身性疾病的部分对疾病的贡献： 免疫细胞和细胞外纳米颗粒。适当的基础设施已经到位，以支持患者- 基于研究。我们特别强调以下关键的概念和技术创新， 我们的优势，包括一个已建立的儿科SLE队列，随后是经验丰富的临床医生， 参与翻译研究的特殊记录 虽然最初的重点将是研究儿童系统性红斑狼疮（SLE），外推 该中心对成人SLE以及其他SAD情况的研究结果将继续下去，特别是在 ACE合作努力。 威尔康奈尔大学医学院的Drukier儿童健康研究所聚集了一个多学科的 儿科基础和以患者为导向的研究人员团队，具有免疫学、自身免疫、癌症 生物学，分子生物学，生物信息学和软件工程师，他们与临床专家一起工作， 自身免疫，癌症，过敏和传染病-从床到板凳，从板凳到床-了解 并治疗这些疾病。研究所还在地方、国家和国际各级建立了强有力的 合作。帕斯夸尔博士的团队在人类免疫学领域有着悠久的生产性研究历史。 自身炎症和自身免疫性疾病。莱登博士的团队开创了外泌体研究的先河， 外泌体，以及这些颗粒如何将其货物水平转移到受体细胞，从而作为载体 在生理和病理条件下的细胞间通讯。拟议的中心是一个自然的 这是这些团体非常互补的专业知识的结果，并准备好协同工作， 人类自身免疫领域的临床和基础发现。 .